Search for "cobalt" in Full Text gives 151 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 2194–2201, doi:10.3762/bjoc.9.258
Graphical Abstract
Figure 1: Several natural occurring anthracycline antibiotics.
Scheme 1: Total synthesis of daunomycinone 6 according to Hansen.
Scheme 2: Synthesis of simplified anthracycline derivatives.
Scheme 3: Retrosynthetic analysis of anthracycline aglycone mimics. Si: any silyl group.
Scheme 4: Synthetic route for the synthesis of various dialkynes 16. aSi: TMS, SiMe2Bn (2.0 equiv); Si: SiMe2...
Scheme 5: Silyl ether synthesis and domino carbopalladation reaction. R,R (Glc): isopropylidene. R,R (Gal): b...
Scheme 6: Derivatisation of anthracycline derivatives. aR,R (Glc): isopropylidene. R,R (Gal): benzylidene. Re...
Beilstein J. Org. Chem. 2013, 9, 2028–2032, doi:10.3762/bjoc.9.239
Graphical Abstract
Figure 1: Structure of the guaiane (−)-oxyphyllol (1).
Scheme 1: Retrosynthetic analysis for (−)-oxyphyllol (1) and structures of the guaiane sesquiterpenes (+)-ori...
Scheme 2: Attempted selective deoxygenation of diol 7. a) 1 mol % K2OsO4, NMO, acetone, water, THF, rt, 97%, ...
Scheme 3: Conversion of 4 to 1. a) 20 mol % Co(acac)2, PhSiH3, 1 atm O2, THF, 0°C, 82%, diastereomeric ratio ...
Beilstein J. Org. Chem. 2013, 9, 1578–1588, doi:10.3762/bjoc.9.180
Graphical Abstract
Scheme 1: Heck reaction of olefins with aryl halides and arylboronic acids.
Scheme 2: Synthesis of imidazole-based SPO–Pd complex 6.
Beilstein J. Org. Chem. 2013, 9, 342–391, doi:10.3762/bjoc.9.39
Graphical Abstract
Figure 1: Change of electron distribution between HS and LS states of an octahedral iron(II) coordination com...
Figure 2: Types of spin transition curves in terms of the molar fraction of HS molecules, γHS(T), as a functi...
Figure 3: Single crystal UV–vis spectra of the spin crossover compound [Fe(ptz)6](BF4)2 (ptz = 1-propyltetraz...
Figure 4: Thermal spin crossover in [Fe(ptz)6](BF4)2 (ptz = 1-propyltetrazole) recorded at three different te...
Figure 5: (a) Mössbauer spectra of the LS compound [Fe(phen)3]X2 recorded over the temperature range 300–5 K....
Figure 6: (left) Demonstration of light-induced spin state trapping (LIESST) in [Fe(ptz)6]BF4)2 with 57Fe Mös...
Figure 7: Schematic representation of the pressure influence (p2 > p1) on the LS and HS potential wells of an...
Figure 8: χMT versus T curves at different pressures for [Fe(phen)2(NCS)2], polymorph II. (Reproduced with pe...
Figure 9: Molecular structure (a) and γHS(T) curves at different pressures for [CrI2(depe)2] (b) (Reproduced ...
Figure 10: HS molar fraction γHS versusT at different pressures for [Fe(phy)2](BF4)2. The hysteresis loop broa...
Figure 11: Proposed structure of the polymeric [Fe(4R-1,2,4-triazole)3]2+ spin crossover cation (a) and plot o...
Figure 12: Temperature dependence of the HS fraction γHS(T), determined from Mössbauer spectra of [Fe(II)xZn1-x...
Figure 13: Influence of the noncoordinated anion on the spin transition curve γHS(T) near the transition tempe...
Figure 14: Spin transition curves γHS(T) for different solvates of the SCO complexes. [Fe(II)(2-pic)3]Cl2·Solv...
Figure 15: ST curves γHS(T) of the deuterated solvates of [Fe(II)(2-pic)3]Cl2·Solv with Solv = C2D5OH and C2H5...
Figure 16: Sketch of the two-step spin transition; [LS–LS] pair is diamagnetic, [LS–HS] is paramagnetic and th...
Figure 17: (left) Temperature dependence of χMT for {[Fe(L)(NCX)2]2bpym}(L = bpym or bt and X = S or Se). (rig...
Figure 18: Temperature dependence of χMT for [bpym, NCS−] (left) and [bpym, NCSe−] (right) at different pressu...
Figure 19: 57Fe Mössbauer spectra of [bpym, NCSe−] measured at 4.2 K at zero field (a) and at 5 T (b) (see tex...
Figure 20: Temperature dependence of χMT for [Fe2(L)3](ClO4)4·2H2O showing a complete two-step spin conversion...
Figure 21: (a) View of the dinuclear unit in the crystal structure of [Fe2(Hsaltrz)5(NCS)4]·4MeOH. (b) Tempera...
Figure 22: (left) AFM pattern recorded in tapping mode at room temperature on hexagonal single crystals of [Fe3...
Figure 23: (right) Stepwise SCO in an Fe4 [2 × 2] grid, which reveals a smooth magnetic profile under ambient ...
Figure 24: (left) View of the discrete nanoball made of Fe(II) SCO units as well as Cu(I) building blocks. (ri...
Figure 25:
(left) Linear dependency between T1/2 in the heating (Δ) and cooling () modes versus the anion volu...
Figure 26: (left) View of the linear chain structure of [Fe(1,2-bis(tetrazol-1-yl)propane)3]2+ along the a axi...
Figure 27: (left) View of the 2D layered structure of [Fe(btr)2(NCS)2]·H2O (at 293 K). The water molecules (in...
Figure 28: (left) Three interpenetrated square networks for [Fe(bpb)2(NCS)2]·MeOH. (right) χMT versus T plot s...
Figure 29: Part of the crystal structure of [Fe{N(entz)3}](BF4)2 (T = 293 K) [335,336]. (Reproduced with permission fro...
Figure 30: (left) Projection of the crystal structure of [Fe(btr)3](ClO4)2 along the c axis revealing a 3D str...
Figure 31: Size-dependent SCO properties in [Fe(pz)Pt(CN)4] (left), change of color upon spin state transition...
Figure 32: Schematic showing the epitaxial growth of polymer {Fe(pz)[Pt(CN)4]} and the spin transition propert...
Figure 33: Microcontact printing (μCP) of nanodots on Si-wafer of [Fe(ptz)6](BF4)2 after deposition of crystal...
Figure 34: (left) Projection of the two independent cations of [Fe(C6–trenH)]2+ with atom numbering scheme (15...
Figure 35: (a) χMT versus T for [Fe(C16-trenH)]Cl2·0.5H2O and variation of the distance d with temperature (T)...
Figure 36: Schematic illustration of the structure of compounds [Fe(Cn-tba)3]X2 adopting a columnar mesophase ...
Figure 37: Temperature dependence of the magnetic moment (M) at 1000 Oe and DSC profiles (inset; 5 °C/min) of ...
Figure 38: Porous structure of the SCO-PMOFs {Fe(pz)[M(II)(CN)4]} (left), representation of the host–guest int...
Figure 39: Porous structure of the guest-free SCO-PMOF’s {Fe(pz)[M(II)(CN)4]} (left), magnetic properties of t...
Figure 40: (left) The 3D porous structure of {Fe(pz)[Pt(CN)4]}·0.5(CS(NH2)2) (1) and {Fe(pz)[Pd(CN)4]}·1.5H2O·...
Figure 41: Top: The 3D porous structure of {Fe(dpe)[Pt(CN)4]}·phenazine in a direction close to [101] emphasiz...
Figure 42: View of the segregated stacking of [Ni(dmit)2]− and [Fe(sal2-trien)]+ in [Fe(qsal)2][Ni(dmit)2]3·CH3...
Figure 43: Thin films based on Fe(III) compounds coordinated to Terthienyl-substituted QsalH ligands [434] together...
Figure 44: Left: Temperature-dependent emission spectra for [Fe2(Hsaltrz)5(NCS)4]·4MeOH at λex = 350 nm over t...
Beilstein J. Org. Chem. 2013, 9, 278–302, doi:10.3762/bjoc.9.34
Graphical Abstract
Scheme 1: Variation of substrates for carbomagnesiation and carbozincation in this article.
Scheme 2: Copper-catalyzed arylmagnesiation and allylmagnesiation of alkynyl sulfone.
Scheme 3: Copper-catalyzed four-component reaction of alkynyl sulfoxide with alkylzinc reagent, diiodomethane...
Scheme 4: Rhodium-catalyzed reaction of aryl alkynyl ketones with arylzinc reagents.
Scheme 5: Allylmagnesiation of propargyl alcohol, which provides the anti-addition product.
Scheme 6: Negishi’s total synthesis of (Z)-γ-bisabolene by allylmagnesiation.
Scheme 7: Iron-catalyzed syn-carbomagnesiation of propargylic or homopropargylic alcohol.
Scheme 8: Mechanism of iron-catalyzed carbomagnesiation.
Scheme 9: Regio- and stereoselective manganese-catalyzed allylmagnesiation.
Scheme 10: Vinylation and alkylation of arylacetylene-bearing hydroxy group.
Scheme 11: Arylmagnesiation of (2-pyridyl)silyl-substituted alkynes.
Scheme 12: Synthesis of tamoxifen from 2g.
Scheme 13: Controlling regioselectivity of carbocupration by attaching directing groups.
Scheme 14: Rhodium-catalyzed carbozincation of ynamides.
Scheme 15: Synthesis of 4-pentenenitriles through carbometalation followed by aza-Claisen rearrangement.
Scheme 16: Uncatalyzed carbomagnesiation of cyclopropenes.
Scheme 17: Iron-catalyzed carbometalation of cyclopropenes.
Scheme 18: Enantioselective carbozincation of cyclopropenes.
Scheme 19: Copper-catalyzed facially selective carbomagnesiation.
Scheme 20: Arylmagnesiation of cyclopropenes.
Scheme 21: Enantioselective methylmagnesiation of cyclopropenes without catalyst.
Scheme 22: Copper-catalyzed carbozincation.
Scheme 23: Enantioselective ethylzincation of cyclopropenes.
Scheme 24: Nickel-catalyzed ring-opening aryl- and alkenylmagnesiation of a methylenecyclopropane.
Scheme 25: Reaction mechanism.
Scheme 26: Nickel-catalyzed carbomagnesiation of arylacetylene and dialkylacetylene.
Scheme 27: Nickel-catalyzed carbozincation of arylacetylenes and its application to the synthesis of tamoxifen....
Scheme 28: Bristol-Myers Squibb’s nickel-catalyzed phenylzincation.
Scheme 29: Iron/NHC-catalyzed arylmagnesiation of aryl(alkyl)acetylene.
Scheme 30: Iron/copper-cocatalyzed alkylmagnesiation of aryl(alkyl)acetylenes.
Scheme 31: Iron-catalyzed hydrometalation.
Scheme 32: Iron/copper-cocatalyzed arylmagnesiation of dialkylacetylenes.
Scheme 33: Chromium-catalyzed arylmagnesiation of alkynes.
Scheme 34: Cobalt-catalyzed arylzincation of alkynes.
Scheme 35: Cobalt-catalyzed formation of arylzinc reagents and subsequent arylzincation of alkynes.
Scheme 36: Cobalt-catalyzed benzylzincation of dialkylacetylene and aryl(alkyl)acetylenes.
Scheme 37: Synthesis of estrogen receptor antagonist.
Scheme 38: Cobalt-catalyzed allylzincation of aryl-substituted alkynes.
Scheme 39: Silver-catalyzed alkylmagnesiation of terminal alkyne.
Scheme 40: Proposed mechanism of silver-catalyzed alkylmagnesiation.
Scheme 41: Zirconium-catalyzed ethylzincation of terminal alkenes.
Scheme 42: Zirconium-catalyzed alkylmagnesiation.
Scheme 43: Titanium-catalyzed carbomagnesiation.
Scheme 44: Three-component coupling reaction.
Scheme 45: Iron-catalyzed arylzincation reaction of oxabicyclic alkenes.
Scheme 46: Reaction of allenyl ketones with organomagnesium reagent.
Scheme 47: Regio- and stereoselective reaction of a 2,3-allenoate.
Scheme 48: Three-component coupling reaction of 1,2-allenoate, organozinc reagent, and ketone.
Scheme 49: Proposed mechanism for a rhodium-catalyzed arylzincation of allenes.
Scheme 50: Synthesis of skipped polyenes by iterative arylzincation/allenylation reaction.
Scheme 51: Synthesis of 1,4-diorganomagnesium compound from 1,2-dienes.
Scheme 52: Synthesis of tricyclic compounds.
Scheme 53: Manganese-catalyzed allylmagnesiation of allenes.
Scheme 54: Copper-catalyzed alkylmagnesiation of 1,3-dienes and 1,3-enynes.
Scheme 55: Chromium-catalyzed methallylmagnesiation of 1,6-diynes.
Scheme 56: Chromium-catalyzed allylmagnesiation of 1,6-enynes.
Scheme 57: Proposed mechanism of the chromium-catalyzed methallylmagnesiation.
Beilstein J. Org. Chem. 2013, 9, 180–184, doi:10.3762/bjoc.9.21
Graphical Abstract
Scheme 1: Synthesis of various heterocycles by a tandem A3 coupling/cycloisomerization strategy.
Scheme 2: A plausible mechanistic pathway.
Beilstein J. Org. Chem. 2012, 8, 1771–1777, doi:10.3762/bjoc.8.202
Graphical Abstract
Scheme 1: Copper-catalyzed step-economical C–H arylation-based cascade reaction.
Scheme 2: Copper-catalyzed sequential catalysis with alkyne 1a.
Scheme 3: Copper-catalyzed reaction sequence using alkyl bromides 2. General reaction conditions: 1 (1.00 mmo...
Scheme 4: Nonsequential cascade synthesis of fully substituted triazoles 4. General reaction conditions: 1 (1...
Scheme 5: Copper-catalyzed one-pot twofold C–H/N–H arylation with azoles 5. aReaction performed at 120 °C.
Beilstein J. Org. Chem. 2012, 8, 1536–1542, doi:10.3762/bjoc.8.174
Graphical Abstract
Scheme 1: (a) Cobalt-catalyzed C2-alkenylation of N-pyrimidylindole, (b) ortho-alkylation of aryl imine, and ...
Scheme 2: Addition of N-pyrimidylindoles to vinylsilanes.
Scheme 3: Addition of N-pyrimidylindole to norbornene (a) and 1-octene (b).
Scheme 4: Gram-scale reaction and deprotection of N-pyrimidyl group.
Beilstein J. Org. Chem. 2012, 8, 100–106, doi:10.3762/bjoc.8.10
Graphical Abstract
Figure 1: Structures of neuraminidase inhibitors.
Scheme 1: Isoxazoline-fused β-aminocyclopentanecarboxylate regio- and stereoisomers [8].
Scheme 2: Treatment of isoxazoline-fused amino ester 2 with NaBH4.
Scheme 3: Reduction with Pd/C in the presence of HCO2NH4.
Scheme 4: Transformation of isoxazoline-fused cispentacin stereoisomer 2 into multifunctionalized β-amino aci...
Figure 2: ORTEP diagram of 12 showing the atomic labeling scheme. The thermal ellipsoids are drawn at the 20%...
Scheme 5: Synthesis of multifunctionalized β-amino acid derivatives 13–16. Reaction conditions: NaBH4, NiCl2,...
Beilstein J. Org. Chem. 2011, 7, 1075–1094, doi:10.3762/bjoc.7.124
Graphical Abstract
Scheme 1: AuCl3-catalyzed benzannulations reported by Yamamoto.
Scheme 2: Synthesis of 9-oxabicyclo[3.3.1]nona-4,7-dienes from 1-oxo-4-oxy-5-ynes [40].
Scheme 3: Stereocontrolled oxacyclization/(4 + 2)-cycloaddition cascade of ketone–allene substrates [43].
Scheme 4: Gold-catalyzed synthesis of polycyclic, fully substituted furans from 1-(1-alkynyl)cyclopropyl keto...
Scheme 5: Gold-catalyzed 1,3-dipolar cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with nitrones [47].
Scheme 6: Enantioselective 1,3-dipolar cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with nitrones [48].
Scheme 7: Gold-catalyzed 1,3-dipolar cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with α,β-unsaturated imine...
Scheme 8: Gold-catalyzed (4 + 3) cycloadditions of 1-(1-alkynyl)oxiranyl ketones [50].
Scheme 9: (3 + 2) Cycloaddition of gold-containing azomethine ylides [52].
Scheme 10: Gold-catalyzed generation and reaction of azomethine ylides [53].
Scheme 11: Gold-catalyzed intramolecular (4 + 2) cycloadditions of unactivated alkynes and dienes [55].
Scheme 12: Gold-catalyzed preparation of bicyclo[4.3.0]nonane derivatives from dienol silyl ethers [59].
Scheme 13: Gold(I)-catalyzed intramolecular (4 + 2) cycloadditions of arylalkynes or 1,3-enynes with alkenes [60].
Scheme 14: Gold(I)-catalyzed intermolecular (2 + 2) cycloaddition of alkynes with alkenes [62].
Scheme 15: Metal-catalyzed cycloaddition of alkynes tethered to cycloheptatriene [65].
Scheme 16: Gold-catalyzed cycloaddition of functionalized ketoenynes: Synthesis of (+)-orientalol F [68].
Scheme 17: Gold-catalyzed intermolecular cyclopropanation of enynes with alkenes [70].
Scheme 18: Gold-catalyzed intermolecular hetero-dehydro Diels–Alder cycloaddition [72].
Figure 1: Gold-catalyzed 1,2- or 1,3-acyloxy migrations of propargyl esters.
Scheme 19: Gold(I)-catalyzed stereoselective olefin cyclopropanation [74].
Scheme 20: Reaction of propargylic benzoates with α,β-unsaturated imines to give azepine cycloadducts [77].
Scheme 21: Gold-catalyzed (3 + 3) annulation of azomethine imines with propargyl esters [81].
Scheme 22: Gold(I)-catalyzed isomerization of 5-en-2-yn-1-yl acetates [83].
Scheme 23: (3 + 2) and (2 + 2) cycloadditions of indole-3-acetates 41 [85,86].
Scheme 24: Gold(I)-catalyzed (2 + 2) cycloaddition of allenenes [87].
Scheme 25: Formal (3 + 2) cycloaddition of allenyl MOM ethers and alkenes [90].
Scheme 26: (4 + 3) Cycloadditions of allenedienes [97,98].
Scheme 27: Gold-catalyzed transannular (4 + 3) cycloaddition reactions [101].
Scheme 28: Gold(I)-catalyzed (4 + 2) cycloadditions of allenedienes [102].
Scheme 29: Enantioselective gold(I)-catalyzed (4 + 2) cycloadditions of allenedienes [88,102,104].
Scheme 30: (3 + 2) versus (2 + 2) Cycloadditions of allenenes [87,99].
Figure 2: NHC ligands with different π-acceptor properties [106].
Scheme 31: (3 + 2) versus (2 + 2) Cycloadditions of allenenes [106].
Scheme 32: Gold(I)-catalyzed intermolecular (4 + 2) cycloaddition of allenamides and acyclic dienes [109].
Beilstein J. Org. Chem. 2011, 7, 997–1002, doi:10.3762/bjoc.7.112
Graphical Abstract
Scheme 1: Addition of nucleophiles onto activated imines (A) or iminiums (B).
Scheme 2: Activation of the aldimine with MsCl.
Beilstein J. Org. Chem. 2011, 7, 886–891, doi:10.3762/bjoc.7.101
Graphical Abstract
Scheme 1: Synthesis of symmetrical aryl sulfides catalyzed by copper oxide nanoparticles.
Beilstein J. Org. Chem. 2011, 7, 866–877, doi:10.3762/bjoc.7.99
Graphical Abstract
Scheme 1: Gold-catalyzed propargylic substitutions.
Scheme 2: Propargylic substitution: scope of substrates.
Scheme 3: Propargylic substitutions on allylic/propargylic substrates.
Scheme 4: Direct propargylic substitutions: Scope of nucleophiles.
Scheme 5: Meyer–Schuster rearrangements.
Scheme 6: Silyl-protected propargyl alcohols in propargylic substitutions.
Scheme 7: Acetylacetone as nucleophile in direct propargylic substitution.
Scheme 8: Enantiomerically enriched propargylic alcohols.
Scheme 9: Scope of ‘activated’ alcohols in direct substitution reactions.
Scheme 10: BF3 vs AuCl3 in propargylic substitutions [25].
Scheme 11: The use of bis-nucleophiles in direct propargylic substitutions.
Scheme 12: Tandem reactions from protected hydroxylamines and propargylic alcohols. P = Cbz, PhSO2.
Scheme 13: Tentative hydrolysis of bis-adduct 24a.
Scheme 14: Iron-catalyzed propargylic substitutions.
Scheme 15: Isoxazolines formation.
Scheme 16: Addition of nucleophiles to isoxazolines.
Scheme 17: Potential mechanistic pathways.
Scheme 18: Synthesis of furans from homoproargylic alcohols.
Scheme 19: Synthesis of furans.
Scheme 20: Propargylic substitutions: Synthetic applications. GH2 = Grubbs–Hoveyda 2nd generation catalyst.
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2010, 6, 1174–1179, doi:10.3762/bjoc.6.134
Graphical Abstract
Scheme 1: Lipase-catalyzed acetylation of racemic benzylic secondary alcohol [(RS)-4] and its application.
Scheme 2: FeCl3-meditated synthesis of bis-imines.
Scheme 3: Preparation of racemic 3-(1-hydroxyethyl)phenyl ethyl(methyl)carbamate [(RS)-4]
Scheme 4: Proposed reaction mechanism of lipase-catalyzed acetylation of racemic alcohol 4.
Scheme 5: Complete synthesis of rivastigmine.
Beilstein J. Org. Chem. 2010, 6, 1132–1148, doi:10.3762/bjoc.6.130
Graphical Abstract
Figure 1: Copolymerization of 2 monomers A and B with different polarities in direct miniemlusions with the d...
Figure 2: Interfacial alternating radical copolymerization between dibutyl maleate and vinyl gluconamide for ...
Figure 3: Chemical structures of the surfmers for radical polymerization in miniemulsions: a: sodium vinylben...
Scheme 1: Synthesis of the macroinitiator for ROMP in direct miniemulsion [71].
Figure 4: Monomers used in ionic miniemulsion polymerization. a: octamethylcyclotetrasiloxane [9,74], b: 1,3,5-tris...
Figure 5: Enzymatic reactions in miniemulsion droplets (reproduced with permission from [91]. Copyright (2003) Wi...
Figure 6: Chemical structure of a: polyaniline (leucoemeraldine), b: polypyrrole, c: poly(ethylene dioxythiop...
Figure 7: Transmission electron micrograph of polyurethane capsules synthesized by interfacial polyaddition i...
Figure 8: Schematics for the polycondensation reaction between hydrophobic alcohols and carboxylic acids surr...
Scheme 2: Polyimide from the reaction performed in the ionic liquid 1-ethyl-3-methylimidazolium bis(trifluoro...
Figure 9: a: TEM micrograph of the cubic structures, b: proposed mechanism for the production of the nanocube...
Beilstein J. Org. Chem. 2010, 6, 1099–1105, doi:10.3762/bjoc.6.126
Graphical Abstract
Figure 1: Starting allylcarboranes 1a–1c and O-allylcyclodextrins 2a–2c.
Scheme 1: Cross-metathesis of allylcarboranes 1 and O-allylcyclodextrins 2.
Beilstein J. Org. Chem. 2010, 6, No. 53, doi:10.3762/bjoc.6.53
Graphical Abstract
Scheme 1: Synthesis of twofold iodinated bis(benzo[b]thiophenyl)perfluorocyclopentene 4.
Scheme 2: Synthesis of terpyridinyl boronic acids 9a and 9b.
Scheme 3: Synthesis of the bis(terpyridinyl)diarylethenes 10a and 10b.
Scheme 4: Photochromic reaction of the free ligand 10a.
Figure 1: UV–vis-spectra of 10a before (solid), after UV-irradiation (dashed) and after irradiation with vis ...
Scheme 5: Synthesis of the binuclear Ru(II)-complex 12.
Figure 2: UV–vis-spectra of 12 before (solid), after UV-irradiation (dashed) and after irradiation with vis l...
Figure 3: UV–vis-spectra of 12 before (dashed), after UV-irradiation (dotted), the difference (solid) and fre...
Figure 4: UV–vis-spectra of [Fe2+@10a] before (solid), after UV-irradiation (dashed) and after irradiation wi...
Figure 5: UV–vis-spectra of [Zn2+@10a] before (solid), after UV-irradiation (dashed) and after irradiation wi...
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
Beilstein J. Org. Chem. 2009, 5, No. 82, doi:10.3762/bjoc.5.82
Graphical Abstract
Figure 1: Training set of 19 metal-salens.
Figure 2: Correlation between electron affinity (EA) and Hammett σp parameter in the training set (R2 = 0.76,...
Figure 3: Correlation between Epc and EA for the Ni, Co, and Cu training set metal-salens (R2 = 0.93, 0.17 (0...
Figure 4: Comparison of experimental and predicted Epc for all training set metal-salens.
Figure 5: Test set of 14 metal-salens.
Beilstein J. Org. Chem. 2009, 5, No. 45, doi:10.3762/bjoc.5.45
Graphical Abstract
Scheme 1: Synthesis of 2-diethanolaminoborate-1,3-butadiene.
Figure 1: Molecular structure of boron substituted diene 2.
Scheme 2: Diels–Alder reactions.
Scheme 3: Cross coupling reactions.
Beilstein J. Org. Chem. 2009, 5, No. 2, doi:10.3762/bjoc.5.2
Graphical Abstract
Scheme 1: Products obtained by the reaction of pyrrole and acetone with bismuth(III).
Beilstein J. Org. Chem. 2007, 3, No. 28, doi:10.1186/1860-5397-3-28
Graphical Abstract
Scheme 1: Planned construction for morpholinones 3 from amino acid and glycidyl derivatives 1 and 2. R1, R3 =...
Scheme 2: Synthesis of pyrrolidinone-fused heterocycles from a glycidyl substituted pyroglutamic acid ester 5...
Figure 1: Structure of oxidation product 10a in the crystal.
Scheme 3: Special product conformers, by-products and intermediates of the transformation of 7.
Beilstein J. Org. Chem. 2007, 3, No. 21, doi:10.1186/1860-5397-3-21
Graphical Abstract
Scheme 1: Saigo's cycloisomerisation reaction under Pauson-Khand conditions.
Scheme 2: Pauson-Khand reaction and tether-cleavage in wet acetonitrile.
Scheme 3: Silyl-tethered allenic Pauson-Khand reaction reported by Brummond.
Scheme 4: Intramolecular Pauson-Khand reaction of allyldimethyl- and allyldiphenylsilyl propargyl ethers repo...
Scheme 5: Synthesis and attempted Pauson-Khand reactions of vinyldimethylsilyl- and vinyldiphenylsilyl ethers....
Figure 1: Functionalised acetylenes prepared and used in silyl ether-tethered Pauson-Khand reactions. Yields ...
Figure 2: Chain-functionalised acetylenes prepared and used in silyl ether-tethered Pauson-Khand reactions. Y...
Figure 3: Possible structure of THF-oxidation/insertion product.
Scheme 6: Model Pauson-Khand reaction of allyltrimethylsilane.
Scheme 7: Preparation of allyldiisopropylsilyl ethers.
Scheme 8: Pauson-Khand reaction of allyldiisopropylsilyl ethers.
Scheme 9: Preparation of allyldiisopropylsilanes.
Scheme 10: Attempted Mitsunobu reactions of diisopropylsilanols.
Scheme 11: Preparation of alkynic diisopropylsilanes.
Scheme 12: Preparation of allyldiisopropylsilyl ethers.
Scheme 13: Preparation of acetals from dichlorodiphenylsilane.
Scheme 14: Attempted Pauson-Khand reaction of allylpropargyldiphenylsilyl acetal.
Scheme 15: Proposed diisopropylsilyl acetal formation.
Scheme 16: Attempted allylpropargyldiisopropylsilyl acetal formation.
Scheme 17: Attempted allylpropargyldiisopropylsilyl acetal formation.
Scheme 18: Preparation of silicon-tethered Pauson-Khand precursors.
Scheme 19: Failed Pauson-Khand reaction of a silicon-tethered substrate.